Does insurance cover Wegovy in Texas?

If you’ve been exploring weight-loss medications or diabetes treatments like Wegovy, Ozempic, or Mounjaro, one of your first questions is probably: Will my insurance pay for this? The short answer is complicated—and it depends on your insurance type, your diagnosis, and where you live.

GLP-1 medications have revolutionized weight management and diabetes care, but their high costs (often over $1,000 per month) make insurance coverage critical for most patients. This guide breaks down everything you need to know about coverage, denials, appeals, and affordable alternatives in 2025.

Understanding GLP-1 Medications: What’s the Difference?

Before diving into insurance, let’s clarify what these medications actually do and how they differ.

Wegovy (Semaglutide for Weight Loss)

FDA-approved for: Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition like high blood pressure or type 2 diabetes.

Wegovy is specifically designed for weight loss and has been shown to help patients lose an average of 15% of their body weight when combined with diet and exercise.

Ozempic (Semaglutide for Type 2 Diabetes)

FDA-approved for: Managing blood sugar in adults with type 2 diabetes, and reducing cardiovascular risk in people with diabetes and heart disease.

While Ozempic and Wegovy contain the same active ingredient (semaglutide), Ozempic is not FDA-approved for weight loss. Using it for weight management is considered ‘off-label’ and typically isn’t covered by insurance for that purpose.

Mounjaro (Tirzepatide for Type 2 Diabetes)

FDA-approved for: Type 2 diabetes management.

Mounjaro works by targeting two hormone receptors (GIP and GLP-1) instead of one, potentially offering even greater blood sugar control and weight loss. Its weight-loss counterpart, Zepbound, was approved in 2023—but like Wegovy, coverage is limited.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

How Insurance Coverage Works for GLP-1 Medications

Commercial Insurance (Employer-Sponsored & Marketplace Plans)

For Diabetes (Ozempic & Mounjaro):
Most commercial insurers cover these medications when prescribed for FDA-approved diabetes treatment. However, you’ll likely face:

• Prior authorization requirements – Your doctor must submit documentation proving you have type 2 diabetes and meet clinical criteria
• Step therapy – Many plans require you to try metformin or another first-line diabetes medication before approving a GLP-1
• Higher copays – These drugs typically sit on Tier 3 or 4, meaning specialty medication pricing (often 20-30% coinsurance)

For Weight Loss (Wegovy):
This is where it gets tricky. Many employer health plans exclude obesity medications entirely to control costs. Even when coverage exists, expect:

• Strict prior authorization with extensive documentation requirements
• BMI thresholds of 30+ (or 27+ with comorbidities like diabetes or sleep apnea)
• Proof of at least 6 months of supervised diet and lifestyle interventions
• Regular re-evaluations to prove the medication is working (usually requiring 5% weight loss within 3-6 months)

According to recent research, fewer than half of large employers cover weight-loss medications, and those that do impose significant barriers to access.

Medicare Coverage

Part D (Prescription Drug Coverage):
Here’s the challenge—Medicare Part D is prohibited by federal law from covering medications used solely for weight loss or ‘cosmetic purposes.’ This means:

• Wegovy is generally NOT covered for weight management
• Exception: Medicare will cover Wegovy if prescribed to reduce cardiovascular risk in obese patients with established heart disease (approved indication as of 2024)
• Ozempic and Mounjaro ARE covered for type 2 diabetes on most Part D formularies

Medicare Advantage:
Some Medicare Advantage plans started offering limited obesity medication coverage in 2025, but it varies widely by plan and typically requires meeting very strict criteria.

Medicaid Coverage (State-by-State Breakdown)

Medicaid coverage for GLP-1 weight-loss drugs is a patchwork across the United States. As of late 2025, only about 13 states cover these medications—and several are now reversing that coverage due to budget pressures.

States with NO coverage for weight-loss GLP-1s:

• Texas – Explicitly excludes all obesity medications for adults
• Florida – No coverage under state Medicaid formulary
• Illinois – No coverage despite covering state employees

States with RESTRICTED coverage (as of December 2025):

• California – Currently covers Wegovy with strict prior authorization, but coverage ENDS January 1, 2026 due to budget constraints
• Pennsylvania – Covered Wegovy starting in 2023, but discontinuing coverage January 2026 for adults
• New York – Maintains coverage with prior authorization and quantity limits

Important note: Even in states without adult coverage, children and adolescents may still qualify under EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) provisions.

When Medicaid does cover these medications, prior authorization almost always requires:

• BMI ≥30 (or ≥27 with weight-related comorbidity)
• Documentation of at least 6 months of lifestyle modification attempts
• Regular follow-up appointments to track progress
• Proof of weight-loss progress to maintain coverage

Side-by-Side Coverage Comparison

Why Do Insurance Companies Deny GLP-1 Medications?

Understanding common denial reasons helps you prepare a stronger case for approval or appeal.

1. Not Meeting BMI or Medical Necessity Criteria

If your documented BMI is 28 and you have no qualifying comorbidities, your Wegovy request will likely be denied. Insurance companies follow specific clinical guidelines—typically BMI ≥30, or ≥27 with conditions like hypertension, type 2 diabetes, or dyslipidemia.

2. Insufficient Documentation of Lifestyle Interventions

Many insurers require proof that you’ve attempted a supervised weight-loss program for at least 6 months. This might include:

• Registered dietitian consultations
• Structured exercise programs
• Physician-supervised diet plans
• Weight logs showing consistent effort

Missing this documentation is one of the most common denial triggers.

3. Failure to Complete Step Therapy

For diabetes medications, insurers often require you to try and fail on cheaper alternatives like metformin before approving Ozempic or Mounjaro. For weight loss, they may require trying older medications like phentermine or orlistat first.

4. Off-Label Use

If your doctor prescribes Ozempic for weight loss (not diabetes), expect a denial. Insurance only covers FDA-approved indications unless you successfully argue medical necessity through appeals.

5. Plan Exclusion

Some employer plans simply exclude ‘weight control’ drugs from their formulary entirely, regardless of medical justification. In these cases, even perfect documentation won’t overcome the policy limitation.

How to Successfully Navigate Prior Authorization

Getting approval for GLP-1 medications requires preparation and persistence. Here’s what works:

Before Your Appointment

Gather documentation:

• Complete weight history (at least 6-12 months)
• Records of diet/exercise programs you’ve tried
• Lab results showing weight-related conditions (blood pressure, cholesterol, A1c)
• List of medications tried for weight loss or diabetes

Working with Your Provider

Your healthcare provider plays a crucial role in the PA process. They’ll need to submit:

• Letter of medical necessity explaining why this specific medication is appropriate
• Documentation of your BMI and qualifying comorbidities
• Records of previous treatment attempts
• Clinical notes supporting the prescription

At Klarity Health, our providers are experienced in navigating insurance requirements for GLP-1 medications. During your telehealth visit, we document everything needed for prior authorization and work directly with your insurance company to maximize approval chances. We accept both insurance and cash-pay options, giving you flexibility in how you access care.

Timeline Expectations

• Initial review: 5-7 business days typically
• Expedited review: Available if medically urgent (24-72 hours)
• Appeals: Can take 2-4 weeks

Pro tip: Follow up every 3-4 days if you haven’t heard back. Squeaky wheels get faster responses.

What to Do When Insurance Says No: Appeals & Alternatives

The Appeals Process

If denied, you have the right to appeal—and success rates are higher than you might think when proper documentation is provided.

Level 1: Internal Appeal

• Submit within 180 days of denial
• Provide additional medical records or letters from specialists
• Emphasize how the medication addresses specific medical conditions (not just cosmetic weight loss)
• Reference clinical guidelines showing the medication’s appropriateness for your situation

Level 2: External ReviewIf your internal appeal fails, request an independent third-party review. This is especially effective when your case clearly meets medical necessity criteria but was denied on technicalities.

What improves appeal success:

• Detailed physician letter of medical necessity
• Evidence of failed attempts with alternative treatments
• Documentation of weight-related health complications (sleep apnea, joint problems, pre-diabetes)
• Clinical studies supporting the medication’s efficacy for your specific situation

Affordable Self-Pay Options

When insurance won’t cover these medications, several programs can dramatically reduce costs:

GoodRx Partnership with Novo Nordisk (Launched November 2025)

• Wegovy or Ozempic: $199/month for the first two fills
• Ongoing price: ~$349/month after introductory period
• Available at most major pharmacies nationwide
• Savings of 60-70% off list price

Manufacturer Savings Programs

Novo Nordisk Programs:

• Wegovy Savings Card – For commercially insured patients: as low as $0 copay (up to $225 off monthly)
• NovoCare Patient Assistance – Free medication for uninsured patients meeting income criteria
• Cash-pay program – $349/month at participating pharmacies

Eli Lilly Programs:

• Mounjaro Savings Card – $25/month for eligible insured patients with type 2 diabetes
• Zepbound (tirzepatide) self-pay – Single-dose vials $299-$449/month through LillyDirect
• Patient Assistance Program – Free medication for qualifying low-income patients

Important Considerations

Generic alternatives: There are currently no FDA-approved generics for these medications. Patents extend into the 2030s.

Compounded medications: Some telehealth companies offer compounded semaglutide or tirzepatide at lower prices ($200-400/month). While this may seem appealing, these are:

• Not FDA-approved
• Not subject to the same quality controls
• Potentially less effective or safe
• May contain different inactive ingredients

The FDA has issued warnings about compounded GLP-1 products, particularly regarding contamination and incorrect dosing.

Telehealth & Insurance: Getting GLP-1 Medications Virtually

The good news: telehealth is widely covered for weight management and diabetes care in 2025. Over 40 states have telehealth parity laws requiring insurers to cover virtual visits the same as in-person care.

What Insurance Covers for Telehealth

Typically covered services:

• Initial evaluation and consultation
• Follow-up appointments
• Nutritional counseling (often a covered preventive benefit)
• Medication management visits
• Mental health support for weight management

Requirements to ensure coverage:

• Use an in-network provider when possible
• Confirm your plan covers telehealth (most do post-pandemic)
• Ensure live video is used (some plans don’t cover phone-only or text consultations)

How Klarity Health Makes It Easier

Klarity Health provides comprehensive telehealth services for weight management with several key advantages:

Provider Availability: We offer appointments often within 24-48 hours, eliminating long waits for specialty weight-loss clinics.

Transparent Pricing: Unlike many providers, we clearly display costs upfront. Whether you’re using insurance or paying cash, you’ll know exactly what to expect.

Dual Payment Options: We accept both major insurance plans and cash-pay, giving you flexibility. If your insurance doesn’t cover GLP-1 medications but does cover the visit, we can bill accordingly—or you can opt for our competitive self-pay rates.

Coordinated Care: Our providers handle prior authorization paperwork, work with your pharmacy on manufacturer savings programs, and provide ongoing support to keep you on track.

Virtual Visit Coverage Tips

1. Verify coverage before your appointment – Call your insurance or check your member portal
2. Get a referral if required – Some plans need PCP authorization for specialist telehealth
3. Use in-network platforms – Saves significantly on out-of-pocket costs
4. Keep records – Document all telehealth visits for insurance and appeals purposes

Frequently Asked Questions

Does insurance cover Wegovy for weight loss if I don’t have diabetes?
It depends on your plan. Many commercial insurers exclude weight-loss medications entirely. Those that do cover Wegovy require BMI ≥30 (or ≥27 with comorbidities) plus documentation of failed lifestyle interventions. Medicare and most Medicaid programs do not cover it solely for weight loss.

Can I use Ozempic for weight loss if insurance won’t cover Wegovy?
While Ozempic and Wegovy contain the same medication, insurance typically won’t cover Ozempic for weight loss (it’s off-label use). However, some doctors prescribe it this way, and manufacturer savings cards may help with costs—but expect insurance denials if you don’t have diabetes.

What’s the fastest way to get prior authorization approved?
Have complete documentation ready before submitting: BMI measurements, comorbidity diagnosis codes, 6+ months of documented diet/exercise attempts, and a detailed letter of medical necessity from your provider. Working with experienced telehealth providers like Klarity Health, who understand insurance requirements, significantly speeds up the process.

If my appeal is denied, what are my options?
You can request an external independent review, switch to self-pay with manufacturer savings programs (often $349-499/month), explore patient assistance programs if you meet income criteria, or consider older weight-loss medications that are more affordable and better covered.

Does Medicaid cover GLP-1 medications?
Only in about 13 states, and that number is shrinking in 2026 as California and Pennsylvania cut coverage due to budget constraints. Texas, Florida, and Illinois don’t cover obesity medications for adults. Check your specific state Medicaid formulary or ask your provider.

Will telehealth visits for weight loss be covered by insurance?
Generally yes—most insurance plans cover telehealth for weight management equivalently to in-person visits, especially after pandemic-era policy changes. Verify your plan covers the specific platform or provider and that they’re in-network.

Take the Next Step Toward Effective Weight Management

Navigating GLP-1 medication coverage can feel overwhelming, but you don’t have to do it alone. Whether you’re battling insurance denials, trying to understand your options, or simply want expert guidance on weight-loss medications, telehealth makes access easier than ever.

At Klarity Health, we specialize in weight management through evidence-based treatments—including GLP-1 medications when appropriate. Our providers understand the insurance landscape, handle prior authorizations efficiently, and offer both insured and cash-pay options with transparent pricing. With appointments often available within 24-48 hours, you can start your journey without the typical clinic wait times.

Ready to explore your options? Visit Klarity Health to schedule a consultation and get personalized guidance on GLP-1 medications, insurance coverage, and affordable alternatives tailored to your specific situation.

Sources & References

1. Aetna Clinical Policy Bulletin – Weight Loss GLP-1 Agonists (May 2024)
2. California DHCS Medi-Cal GLP-1 Coverage Update (December 2025)
3. Forbes – Medicaid Coverage of Weight-Loss Drugs Continues to Lag (August 2025)
4. KFF Issue Brief – Medicaid Coverage of and Spending on GLP-1s (November 2024)
5. GoodRx Press Release – $199 Introductory Pricing for Wegovy/Ozempic (November 2025)

📅 RESEARCH CURRENCY STATEMENT (Verified as of December 17, 2025)

Formularies checked: Aetna Clinical Policy (May 2024); Cigna Formulary (April 2024); Kaiser Permanente update (January 2025); Texas VDP criteria (March 2023); Pennsylvania Medicaid bulletin (August 2024).

Medicaid formularies verified: California DHCS (December 2025); Texas HHSC (March 2023); Florida (no Medicaid coverage per federal exclusion); New York NYRx PDL (October 2025); Pennsylvania DHS (December 2025); Illinois HFS (no coverage as of 2025).

GoodRx prices as of: December 2025 – Novo Nordisk/NovoCare program (effective November 2025); GoodRx press release (November 17, 2025); Lilly pricing updates (December 2025).

Verified coverage status and pricing are accurate as of December 17, 2025. Always check your own insurance formulary for the latest details, as policies can change with new plan years.

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499